---
title: "Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Clinical presentation - signs and symptoms"
description: "Formulary evidence on Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Clinical presentation - signs and symptoms. Topics: Motor symptoms: symmetric proximal and distal limb weakness; Sensory symptoms: numbness, tingling, and sensory ataxia; Neurological signs: reduced or absent tendon reflexes; Pain: neuropathic pain during the disease course; 4 further topics. 8 evidence topics quoted from 8 sources."
canonical: "https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description/clinical-presentation-signs-and-symptoms"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Clinical presentation - signs and symptoms

<a id="heading-2.2.1.6"></a>

## 2.2.1.6 Clinical Presentation - Signs and Symptoms

<a id="topic-2.2.1.6-1"></a>

### Motor symptoms: symmetric proximal and distal limb weakness

> “At initial admission, the most common symptoms were weakness (100% of typical CIDP, 91% of CIDP variants), sensory disturbances (97% of typical CIDP, 93% of CIDP variants), and/or ataxia (both 56%).”

Source: [Quint et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11377626/)

> “The following two commonly reported symptoms had larger ranges between regions, with distal muscle weakness ranging from 42.3% in the US to 75.7% in Japan, and peripheral tingling ranging from 21.7% in China to 64.4% in Europe”

Source: [Querol et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12361836/)

<a id="topic-2.2.1.6-2"></a>

### Sensory symptoms: numbness, tingling, and sensory ataxia

> “For symptoms experienced as an overall cohort, peripheral numbness was the most commonly reported at 70.5%, ranging from 67.4% in the US to 79.6% in Japan.”

Source: [Querol et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12361836/)

> “CIDP manifests typically as an insidious onset of weakness, hypo- or areflexia, numbness, paresthesia, and sensory ataxia with a progressive or relapsing–remitting pattern”

Source: [Querol et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9294101/)

<a id="topic-2.2.1.6-3"></a>

### Neurological signs: reduced or absent tendon reflexes

> “In both typical CIDP and CIDP variants, most patients (72% in typical and 60% in CIDP variants) exhibited areflexia in at least one muscle tendon reflex.”

Source: [Quint et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11377626/)

<a id="topic-2.2.1.6-4"></a>

### Pain: neuropathic pain during the disease course

> “The pooled estimate of the prevalence of pain at any point within the course of CIDP was 46% (95% CI 36–57%).”

Source: [Michaelides et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6857093/)

<a id="topic-2.2.1.6-5"></a>

### Movement symptoms: tremor and myoclonus

> “Of the 124 included CIDP patients, 86 patients (69%, 95% CI 61 to 77%) currently had clinically tremulous movements (CTM), mainly consisting of tremor but also of myoclonus or both. Lifetime prevalence was 76% (95% CI 68 to 83%).”
> “CTM were associated with CIDP-related and tremor-related disability and upper arm sensory impairment.”

Source: [Pallada et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13691695/)

<a id="topic-2.2.1.6-6"></a>

### Fatigue

> “For all patients, the mean (SD) FACIT fatigue score was 35.0 (11.1). The majority of patients (52.7%) had scores between 36 and 51. Around one in ten (10.6%) scored between 0 and 19, indicative of severe fatigue”

Source: [Querol et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12361836/)

<a id="topic-2.2.1.6-7"></a>

### Autonomic symptoms: sudomotor, cardiovagal, gastrointestinal, and genitourinary dysfunction

> “Autonomic symptoms were uncommon, mainly gastrointestinal (9/47; 19%) and genitourinary (8/47; 17%). Autonomic deficits (CASS ≥1) were frequent (22/47; 47%) but very mild (CASS, 0.8 ± 0.9; CASS ≤3, all cases). Deficits were predominantly sudomotor (16/47; 34%) and cardiovagal (10/47; 21%) with relative adrenergic sparing (4/47; 9%).”

Source: [Figueroa et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3306161/)

> “Thirty-four (89%) patients had features of autonomic dysfunction. Thirty-three (86%) patients had cardiovagal dysfunction, 21 (55%) had adrenergic dysfunction, and 24 (63%) had sudomotor dysfunction. Autonomic dysfunction was mild to moderate in the majority (86%).”

Source: [Pasangulapati et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5586124/)

<a id="topic-2.2.1.6-8"></a>

### Cranial nerve involvement in the multifocal variant

> “It predominantly affects the upper limbs, although lower limbs can be affected as well, while cranial nerve deficits are more common in this phenotype.”

Source: [van Doorn et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10875175/)

## Related pages
- [Claseprubart (DNTH103): Chronic inflammatory demyelinating polyneuropathy](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Terms and abbreviations](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/terms-and-abbreviations.md)
- [Claseprubart (DNTH103): Chronic inflammatory demyelinating polyneuropathy](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/executive-summary) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/executive-summary.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Product information and disease description](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Clinical evidence](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/clinical-evidence.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Economic information and modeling report](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/economics) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/economics.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: References](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/references) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/references.md)
